KAI1 suppresses HIF-1α and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Park, Jung Jin ^a,c   Jin, Yeung B ^a   Lee, Yoon Jin ^a   Lee, Jae Seon ^a   Lee, Yun Sil ^b   Ko, Young Gyu ^c   Lee, Minyoung ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Ewha Womans University   (South Korea)

^c Korea University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD82 ANTIGEN; COMPLEMENTARY DNA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUCIFERASE; PROTEIN CDCP1; PROTEIN TYROSINE KINASE; TETRASPANIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL CLONING; CELL STRAIN PC3; CONTROLLED STUDY; DOWN REGULATION; GENE ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANTIGENS, CD; ANTIGENS, CD82; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUCIFERASES; MALE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SRC-FAMILY KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84862826253     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-81     Document Type: Article

References (47)

1. Smith SC, Theodorescu D. Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer 2009, 9:253-264. 10.1038/nrc2594, 2881216, 19242414.
2. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995, 268:884-886. 10.1126/science.7754374, 7754374.
3. Malik FA, Sanders AJ, Jiang WG. KAI-1/CD82, the molecule and clinical implication in cancer and cancer metastasis. Histol Histopathol 2009, 24:519-530.
4. Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, Barrett JC, Isaacs JT. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996, 56:4387-4390.
5. Miranti CK. Controlling cell surface dynamics and signaling: how CD82/KAI1 suppresses metastasis. Cell Signal 2009, 21:196-211. 10.1016/j.cellsig.2008.08.023, 18822372.
6. Geiger TR, Peeper DS. Metastasis mechanisms. Biochim Biophys Acta 2009, 1796:293-308.
7. Cassavaugh J, Lounsbury KM. Hypoxia-mediated biological control. J Cell Biochem 2011, 112:735-744. 10.1002/jcb.22956, 21328446.
8. Semenza GL. Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 2008, 60:591-597. 10.1002/iub.93, 18506846.
9. Gossage L, Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 2010, 7:277-288. 10.1038/nrclinonc.2010.42, 20368728.
10. Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep 2009, 11:94-101. 10.1007/s11912-009-0015-5, 2873025, 19216840.
11. Andre M, Le Caer JP, Greco C, Planchon S, El Nemer W, Boucheix C, Rubinstein E, Chamot-Rooke J, Le Naour F. Proteomic analysis of the tetraspanin web using LC-ESI-MS/MS and MALDI-FTICR-MS. Proteomics 2006, 6:1437-1449. 10.1002/pmic.200500180, 16404722.
12. Wortmann A, He Y, Deryugina EI, Quigley JP, Hooper JD. The cell surface glycoprotein CDCP1 in cancer-insights, opportunities, and challenges. IUBMB Life 2009, 61:723-730. 10.1002/iub.198, 19514048.
13. Benes CH, Wu N, Elia AE, Dharia T, Cantley LC, Soltoff SP. The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell 2005, 121:271-280. 10.1016/j.cell.2005.02.019, 15851033.
14. Perry SE, Robinson P, Melcher A, Quirke P, Buhring HJ, Cook GP, Blair GE. Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett 2007, 581:1137-1142. 10.1016/j.febslet.2007.02.025, 17335815.
15. Alvares SM, Dunn CA, Brown TA, Wayner EE, Carter WG. The role of membrane microdomains in transmembrane signaling through the epithelial glycoprotein Gp140/CDCP1. Biochim Biophys Acta 2008, 1780:486-496. 10.1016/j.bbagen.2008.01.010, 18269919.
16. Siva AC, Wild MA, Kirkland RE, Nolan MJ, Lin B, Maruyama T, Yantiri-Wernimont F, Frederickson S, Bowdish KS, Xin H. Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model. Cancer Res 2008, 68:3759-3766. 10.1158/0008-5472.CAN-07-1657, 18483259.
17. Zhang XA, He B, Zhou B, Liu L. Requirement of the p130CAS-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration. J Biol Chem 2003, 278:27319-27328. 10.1074/jbc.M303039200, 12738793.
18. Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 2006, 25:2367-2378. 10.1038/sj.onc.1209269, 16331263.
19. Jee B, Jin K, Hahn JH, Song HG, Lee H. Metastasis-suppressor KAI1/CD82 induces homotypic aggregation of human prostate cancer cells through Src-dependent pathway. Exp Mol Med 2003, 35:30-37.
20. Todeschini AR, Dos Santos JN, Handa K, Hakomori SI. Ganglioside GM2-tetraspanin CD82 complex inhibits met and its cross-talk with integrins, providing a basis for control of cell motility through glycosynapse. J Biol Chem 2007, 282:8123-8133. 10.1074/jbc.M611407200, 17215249.
21. Guarino M. Src signaling in cancer invasion. J Cell Physiol 2010, 223:14-26.
22. Edwards J. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opin Investig Drugs 2010, 19:605-614. 10.1517/13543781003789388, 20367532.
23. Piwnica-Worms H, Saunders KB, Roberts TM, Smith AE, Cheng SH. Tyrosine phosphorylation regulates the biochemical and biological properties of pp 60c-src. Cell 1987, 49:75-82. 10.1016/0092-8674(87)90757-4, 3103926.
24. He Y, Wortmann A, Burke LJ, Reid JC, Adams MN, Abdul-Jabbar I, Quigley JP, Leduc R, Kirchhofer D, Hooper JD. Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta. J Biol Chem 2010, 285:26162-26173. 10.1074/jbc.M109.096453, 2924022, 20551327.
25. Razorenova OV, Finger EC, Colavitti R, Chernikova SB, Boiko AD, Chan CK, Krieg A, Bedogni B, LaGory E, Weissman IL, et al. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration. Proc Natl Acad Sci USA 2011, 108:1931-1936. 10.1073/pnas.1011777108, 3033256, 21233420.
26. Chou MT, Anthony J, Bjorge JD, Fujita DJ. The von Hippel-Lindau Tumor Suppressor Protein Is Destabilized by Src: Implications for Tumor Angiogenesis and Progression. Genes Cancer 2010, 1:225-238. 10.1177/1947601910366719, 3014987,3014987, 21212839.
27. Schoenfeld N, Bauer MK, Grimm S. The metastasis suppressor gene C33/CD82/KAI1 induces apoptosis through reactive oxygen intermediates. FASEB J 2004, 18:158-160.
28. Ono M, Handa K, Withers DA, Hakomori S. Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with concurrent glycosylation. Cancer Res 1999, 59:2335-2339.
29. Zismanov V, Lishner M, Tartakover-Matalon S, Radnay J, Shapiro H, Drucker L. Tetraspanin-induced death of myeloma cell lines is autophagic and involves increased UPR signalling. Br J Cancer 2009, 101:1402-1409. 10.1038/sj.bjc.6605291, 2768457, 19755988.
30. Yanez-Mo M, Barreiro O, Gordon-Alonso M, Sala-Valdes M, Sanchez-Madrid F. Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol 2009, 19:434-446. 10.1016/j.tcb.2009.06.004, 19709882.
31. Wang HX, Li Q, Sharma C, Knoblich K, Hemler ME. Tetraspanin protein contributions to cancer. Biochem Soc Trans 2011, 39:547-552. 10.1042/BST0390547, 21428937.
32. Odintsova E, Sugiura T, Berditchevski F. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. Curr Biol 2000, 10:1009-1012. 10.1016/S0960-9822(00)00652-7, 10985391.
33. Knudsen BS, Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res 2004, 91:31-67.
34. Nakashiro K, Hayashi Y, Oyasu R. Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue. Oncol Rep 2003, 10:1149-1153.
35. Destaing O, Planus E, Bouvard D, Oddou C, Badowski C, Bossy V, Raducanu A, Fourcade B, Albiges-Rizo C, Block MR. beta1A integrin is a master regulator of invadosome organization and function. Mol Biol Cell 2010, 21:4108-4119. 10.1091/mbc.E10-07-0580, 2993740, 20926684.
36. Uekita T, Tanaka M, Takigahira M, Miyazawa Y, Nakanishi Y, Kanai Y, Yanagihara K, Sakai R. CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. Am J Pathol 2008, 172:1729-1739. 10.2353/ajpath.2008.070981, 2408431, 18467693.
37. Ikeda J, Oda T, Inoue M, Uekita T, Sakai R, Okumura M, Aozasa K, Morii E. Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Sci 2009, 100:429-433. 10.1111/j.1349-7006.2008.01066.x, 19077003.
38. Deryugina EI, Conn EM, Wortmann A, Partridge JJ, Kupriyanova TA, Ardi VC, Hooper JD, Quigley JP. Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination. Mol Cancer Res 2009, 7:1197-1211. 10.1158/1541-7786.MCR-09-0100, 3068911, 19671673.
39. Miyazawa Y, Uekita T, Hiraoka N, Fujii S, Kosuge T, Kanai Y, Nojima Y, Sakai R. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res 2010, 70:5136-5146. 10.1158/0008-5472.CAN-10-0220, 20501830.
40. Liu H, Ong SE, Badu-Nkansah K, Schindler J, White FM, Hynes RO. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis. Proc Natl Acad Sci USA 2011, 108:1379-1384. 10.1073/pnas.1017228108, 3029734, 21220330.
41. Ikeda JI, Morii E, Kimura H, Tomita Y, Takakuwa T, Hasegawa JI, Kim YK, Miyoshi Y, Noguchi S, Nishida T, Aozasa K. Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells. J Pathol 2006, 210:75-84. 10.1002/path.2026, 16823897.
42. Botelho F, Pina F, Lunet N. VEGF and prostatic cancer: a systematic review. Eur J Cancer Prev 2010, 19:385-392. 10.1097/CEJ.0b013e32833b48e1, 20502342.
43. Clarke NW, Hart CA, Brown MD. Molecular mechanisms of metastasis in prostate cancer. Asian J Androl 2009, 11:57-67. 10.1038/aja.2008.29, 19050684.
44. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995, 375:577-581. 10.1038/375577a0, 7540725.
45. Mohan S, Burk RD. von Hippel-Lindau protein complex is regulated by cell density. Oncogene 2003, 22:5270-5280. 10.1038/sj.onc.1206592, 12917628.
46. Shiao YH, Forsti A, Egevad L, Anderson LM, Lindblad P, Hemminki K. VHL down-regulation and differential localization as mechanisms in tumorigenesis. Kidney Int 2003, 64:1671-1674. 10.1046/j.1523-1755.2003.00257.x, 14531799.
47. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22:4991-5004. 10.1200/JCO.2004.05.061, 15611513.